These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777 [TBL] [Abstract][Full Text] [Related]
4. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas. Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519 [TBL] [Abstract][Full Text] [Related]
5. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. Leu S; von Felten S; Frank S; Boulay JL; Mariani L J Neurooncol; 2016 Apr; 127(2):363-72. PubMed ID: 26780338 [TBL] [Abstract][Full Text] [Related]
6. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263 [TBL] [Abstract][Full Text] [Related]
7. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Juratli TA; Peitzsch M; Geiger K; Schackert G; Eisenhofer G; Krex D Neuro Oncol; 2013 Jun; 15(6):682-90. PubMed ID: 23410661 [TBL] [Abstract][Full Text] [Related]
8. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas. Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454 [TBL] [Abstract][Full Text] [Related]
9. Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas. Hana T; Mukasa A; Nomura M; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Nejo T; Kitagawa Y; Yamazawa E; Takahashi S; Koike T; Kushihara Y; Takami H; Takayanagi S; Aburatani H; Saito N Cancer Sci; 2024 May; 115(5):1706-1717. PubMed ID: 38433527 [TBL] [Abstract][Full Text] [Related]
10. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553 [TBL] [Abstract][Full Text] [Related]
11. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas. Mo H; Magaki S; Deisch JK; Raghavan R J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894 [TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress. Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166 [TBL] [Abstract][Full Text] [Related]
13. IDH1 Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042 [TBL] [Abstract][Full Text] [Related]
14. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry. Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146 [TBL] [Abstract][Full Text] [Related]
15. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705 [TBL] [Abstract][Full Text] [Related]
16. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826 [TBL] [Abstract][Full Text] [Related]
17. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients. Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421 [TBL] [Abstract][Full Text] [Related]
18. Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma. Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Carter BS; Cahill DP; Curry WT; Choi BD Clin Cancer Res; 2024 Sep; 30(18):4068-4076. PubMed ID: 39042445 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087 [TBL] [Abstract][Full Text] [Related]